← Human Trials & Peer-Reviewed Studies
Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization
Plain-language guide to PMID 31227286 (2019): double-blind randomized controlled trial study of hCG (human chorionic gonadotropin).
Key Facts
- PMID
- 31227286
- Journal
- Fertility and sterility
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Kaye L et al. (7 authors)
- DOI
- 10.1016/j.fertnstert.2019.04.034
What This Study Did, in Plain Language
What Was Tested
Researchers studied hCG (human chorionic gonadotropin) in this randomized controlled trial publication.
To characterize corpora lutea (CL) function after gonadotropin-releasing hormone agonist (GnRHa) trigger with the use of adjuvant human chorionic gonadotropin (hCG).
Who Took Part
The age groups tagged for this paper are adults, women only.
Women under 40 years of age at risk of ovarian hyperstimulation syndrome (OHSS) with serum E2 level <4,000 pg/mL.
All subjects underwent ovarian stimulation with the use of a GnRH antagonist protocol.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got hCG (human chorionic gonadotropin) and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on hCG (human chorionic gonadotropin), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the hCG (human chorionic gonadotropin) group a baseline to be compared against.
Secondary analysis of serum from prospective randomized clinical trial.
What Was Measured
The subject headings attached to it are 17-alpha-Hydroxyprogesterone, Biomarkers, Chorionic Gonadotropin, Corpus Luteum, Fertilization in Vitro, Gonadotropin-Releasing Hormone and Infertility, Female.
Author keywords: Gonadotropin-releasing hormone/agonists, corpus luteum maintenance, dual trigger and ovarian hyperstimulation syndrome.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of hCG (human chorionic gonadotropin).
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (Fertility and sterility), a journal based in United States.
More context: the hCG (human chorionic gonadotropin) compound page, all human trials.
Our Notes on the Compound
hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.